1. "Gastrointestinal Oncology Service"
Formats
  1. Journal Article (2302)
  2. Meeting Abstract (1841)
  3. Review (139)
  4. Book Section (123)
  5. Editorial (93)
  6. Guidelines (36)
  7. Correspondence (33)
  8. Conference Paper (23)
  9. Miscellaneous (21)
  10. Research Letter (17)
  11. Book Whole (12)
Groups
  1. Gastrointestinal Oncology Service (4640)
  2. Solid Tumor Oncology Division (4640)
  3. Department of Medicine (4638)
  4. Center for Pancreatic Cancer Research (2270)
  5. Surgery (1040)
  6. Survivorship Research (992)

More Groups

People
  1. Leonard Saltz (790)
  2. Eileen O'Reilly (780)
  3. Ghassan Abou-Alfa (568)
  4. Nancy Kemeny (543)
  5. David Kelsen (537)
  6. David Ilson (433)

More People

Years
  1. 2025 (118)
  2. 2024 (307)
  3. 2023 (362)
  4. 2022 (346)
  5. 2021 (345)
  6. 2020 (326)

More Years

Publications
  1. Journal of Clinical Oncology (1276)
  2. Annals of Oncology (320)
  3. Annals of Surgical Oncology (140)
  4. Cancer (127)
  5. Clinical Cancer Research (107)
  6. Cancer Research (94)

More Publications

Publishers
  1. American Society of Clinical Oncology (1355)
  2. Oxford University Press (447)
  3. Elsevier Inc. (404)
  4. Springer (310)
  5. American Association for Cancer Research (279)
  6. Wiley Blackwell (239)

More Publishers

Results (4640)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • CLARITY-PanTumor01: A phase 2 trial of the claudin 18.2-specific antibody-drug conjugate AZD0901 (CMG901) in patients with CLDN18.2-expressing advanced solid tumors
    Meeting Abstract

    Raufi, A. G.; Goyal, L.; Smyth, E.; Szekeres, P.; Petrone, M.; Hobson, R.; Thress, K.; Origuchi, M.; Nehra, J.; Brown, J. S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Avutometinib/defactinib and gemcitabine/nab-paclitaxel combination in first-line metastatic pancreatic ductal adenocarcinoma: Initial safety and efficacy of phase 1b/2 study (RAMP 205)
    Meeting Abstract

    Lim, K. H.; Spencer, K. R.; Safyan, R. A.; Picozzi, V. J.; Varghese, A. M.; Siolas, D.; Perez, K.; Clift, S.; Denis, L. J.; Bhambhani, V.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • AMPLIFY-7P, a first-in-human safety and efficacy trial of adjuvant mKRAS-specific lymph node targeted amphiphile ELI-002 7P vaccine in patients with minimal residual disease-positive pancreatic and colorectal cancer
    Meeting Abstract

    Devoe, C. E.; Pant, S.; Wainberg, Z. A.; Chung, V.; George, T. J.; Kasi, P. M.; VanWyk, H.; Tavares, A.; Perry, J.; Kheoh, T.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 1/2 study of REGN7075 in combination with cemiplimab (cemi) in patients (pts) with advanced solid tumors: Efficacy and safety results
    Meeting Abstract

    Segal, N. H.; Girda, E.; Sohal, D.; Lakhani, N. J.; Olszanski, A. J.; Fong, L.; Kinnaman, M. D.; Han, H.; Skokos, D.; Casey, K. A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 1b, multicenter, open-label study of valemetostat in combination with DXd antibody drug conjugates (ADCs), trastuzumab deruxtecan (T-DXd) or datopotamab deruxtecan (Dato-DXd), in patients with solid tumors
    Meeting Abstract

    Sands, J.; Tolaney, S. M.; Ueno, N. T.; Spira, A. I.; Yamamoto, N.; Janjigian, Y. Y.; Naito, Y.; Damodaran, S.; Meric-Bernstam, F.; Modi, S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 1/2, safety lead-in and dose expansion, open-label, multicenter trial investigating the safety, tolerability, and preliminary activity of ivosidenib in combination with nivolumab and ipilimumab in previously treated subjects with IDH1-mutated nonresectable or metastatic cholangiocarcinoma
    Meeting Abstract

    Kelley, R. K.; Cleary, J. M.; Sahai, V.; Baretti, M.; Bridgewater, J. A.; Hua, Z.; Gliser, C.; Bian, Y.; Abou-Alfa, G. K.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase 2 study of livmoniplimab in combination with budigalimab in patients with hepatocellular carcinoma
    Meeting Abstract

    Abou-Alfa, G. K.; Chiu, C. F.; Piscaglia, F.; Sangro, B.; Henkel, A.; Fang, H.; Patel, M.; Ping, Z.; Sutherland, C.; Bako, E.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Alliance EAY191-A6: FOLFOX in combination with binimetinib as second-line therapy for patients with advanced biliary tract cancers (BTCs) with MAPK pathway alterations: A ComboMATCH treatment trial
    Meeting Abstract

    Shergill, A.; Liao, C. Y.; Elsaid, M. I.; Al Baghdadi, T.; Ji, Y.; Feldman, D.; George, S.; O'Reilly, E. M.; Meyerhardt, J. A.; Berg, S. A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase 1b study evaluating the efficacy and safety of ABBV-400, a c-Met-targeting antibody-drug conjugate, in select advanced solid tumor indications
    Meeting Abstract

    Perets, R.; Sharma, M.; Strickler, J. H.; Golan, T.; Hollebecque, A.; Henner, W.; Vasilopoulos, A.; Thiele, G. M.; Burns, M. C.; Harding, J. J.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase I/II first-in-human study to evaluate the safety and efficacy of tissue factor-ADC MRG004A in patients with solid tumors
    Meeting Abstract

    Park, W.; Zhang, J.; Dayyani, F.; Shan, J.; Liu, R.; Guo, R.; O'Reilly, E. M.; Liu, Z.; Gao, S.; Wu, X.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save